演題抄録

International Workshop

開催概要
開催回
第54回・2016年・横浜
 

Clinical response of borderline T4 esophageal cancer with docetaxel-cisplatin-5-fluorouracil

演題番号 : IWS3-4

[筆頭演者]
竹内 優志:1 
[共同演者]
竹内 裕也:1、福田 和正:1、須田 康一:1、中村 理恵子:1、和田 則仁:1、川久保 博文:1、北川 雄光:1

1:慶應義塾大学・医学部・一般・消化器外科

 

Background: The patients who have factors of T4 for esophageal cancer are known to need chemoradiotherapy as a primary treatment. On the other hand, the treatment for the patients who have borderline T4 remains controversial. We have administered DCF therapy (70mg/m2 docetaxel and 70mg/ m2 cisplatin on day 1, 750mg/ m2 5-fluorouracil on day 1-5) every 3 weeks for borderline T4 since 2012. In this study, we investigated the clinical response with DCF therapy and assessed the long-term prognosis of these patients.
Methods: We investigated 29 patients who received DCF therapy for esophageal cancer with borderline T4 as a primary treatment. We retrospectively evaluated the pretreatment characteristics, toxicities of chemotherapy and clinical response in all the patients. And examined long-term prognosis using the Kaplan-Meier method and log rank test.
Results: The clinical response rate was 62.1%(18/29). There are toxicities of chemotherapy greater than Grade 3 in 58.6%(19/29) of all patients. Sixteen patients (55.2%) could be performed esophagectomy after DCF therapy, 11 patients (37.9%) received chemoradiotherapy, 1 patient chose different chemotherapy and 1 patient had no more treatment. Pathological response rate was 31.3% (9/29). There were significant differences between the operable esophageal cancer and inoperable in DFS (p=0.046).
Conclusion: We obtained good clinical response and able to perform esophagectomy in more than half of patients. Moreover, it is suggested that knowing the sensitivity of DCF therapy enable us to determine the following combined modality, and to predict prognosis.

キーワード

臓器別:食道

手法別:集学的治療

前へ戻る